Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV EBITDA

EBITDA at other companies

JAN
Janus Living JAN
-$1.85M-152%
Alkermes logo
AlkermesALKS
——

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Current ratio0.9×0.0×

Where this comes from

Calculated from Indivior Pharmaceuticals, Inc. ’s reported figures.

$137.0Mebit+
$2.0MDepreciation Depletion & Amortization
=$139M

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's EBITDA?
Indivior Pharmaceuticals, Inc. (INDV) reported EBITDA of $139M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's EBITDA changed year-over-year?
Indivior Pharmaceuticals, Inc. 's EBITDA increased by 101.4% year-over-year, from $69M to $139M.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's EBITDA?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's EBITDA has grown at a 64.6% compound annual growth rate (CAGR), from -$61M to $272M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.